
Alison J-A Woolford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5484265/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Molecular Cancer Therapeutics, 2021, 20, 1757-1768.	1.9	13
2	Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. Journal of Medicinal Chemistry, 2021, 64, 12286-12303.	2.9	9
3	Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Proteinâ^Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 15949-15972.	2.9	16
4	Structure–Activity and Structure–Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein–Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 4683-4702.	2.9	59
5	Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. Journal of Medicinal Chemistry, 2018, 61, 4978-4992.	2.9	42
6	Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery. Journal of Medicinal Chemistry, 2016, 59, 3991-4006.	2.9	226
7	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA ₂) Discovered through X-ray Fragment Screening. Journal of Medicinal Chemistry, 2016, 59, 5356-5367.	2.9	23
8	Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA ₂). Journal of Medicinal Chemistry, 2016, 59, 10738-10749.	2.9	16
9	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. Journal of Medicinal Chemistry, 2015, 58, 6574-6588.	2.9	76
10	Abstract 2944: AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models Cancer Research, 2013, 73, 2944-2944.	0.4	3
11	Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 445-449.	1.3	34
12	Abstract 2018: Discovery of potent dual inhibitors of both XIAP and cIAP1 using fragment based drug discovery. , 2012, , .		0
13	Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. Journal of Medicinal Chemistry. 2010. 53. 5956-5969.	2.9	230
14	Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. Journal of Medicinal Chemistry, 2010, 53, 5942-5955.	2.9	173
15	Identification of <i>N</i> -(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1 <i>H</i> -pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. Journal of Medicinal Chemistry, 2008, 51, 4986-4999.	2.9	317